Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 42.1
edited by manuelmenendez
on 2025/02/02 20:53
on 2025/02/02 20:53
Change comment:
There is no comment for this version
To version 43.1
edited by manuelmenendez
on 2025/02/05 11:14
on 2025/02/05 11:14
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -18,27 +18,23 @@ 18 18 = **Overview** = 19 19 20 20 21 -The classification and diagnosis of central nervous system (CNS) diseases have long been constrained by traditional phenotype-based approaches ,whichoften fail to capture the complex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changesthat drive diseaseprogression.21 +The classification and diagnosis of central nervous system (CNS) diseases have long been constrained by traditional, phenotype-based approaches that often fail to capture the complex interplay of pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes. Neurodiagnoses redefines this landscape by integrating advanced AI with multi-modal data—including genetics, neuroimaging, biomarkers, and digital health records—to create a more precise, scalable, and data-driven diagnostic system. 22 22 23 -Neurodiagnoses is an open-source AI-powereddiagnosticsystemdesigned forcomplexCNSdisorders,includingneurodegenerativediseases, autoimmuneencephalopathies,priondisorders,andgeneticyndromes.The project aimsto developatridimensionaldiagnostic frameworkwithanAI-poweredannotation system,integratingetiology,molecular biomarkers,andneuroanatomoclinicalcorrelationsforprecise,standardized, andscalableCNSdiseasediagnostics.23 +In addition to these clinical diagnostic approaches, Neurodiagnoses has expanded into a research-oriented platform through the integration of **CNS Digital Twins**. This cutting-edge concept involves creating a personalized digital replica of a patient’s CNS by incorporating multi-omics data (proteomics, genomics, lipidomics, transcriptomics), various neuroimaging modalities, and digital health information. These digital twins enable simulations of disease progression, support the discovery of novel biomarkers, and help identify new therapeutic targets. 24 24 25 - The //TridimensionalDiagnostic Framework// redefinesCNS diseases can be classified and diagnosedbyfocusingon:25 +On this page, you will find: 26 26 27 -* **Axis 1**: Etiology (genetic or other causes of diseases). 28 -* **Axis 2**: Molecular Markers (biomarkers). 29 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 27 +* Detailed descriptions of both the clinical diagnostic tools and the research framework. 28 +* Access to our AI models, data processing pipelines, and digital twin simulations. 29 +* Collaborative resources for researchers, clinicians, and AI developers. 30 +* Guidelines and instructions on how to contribute to and expand the project. 30 30 31 -This methodology enables: 32 32 33 -* Greater precision in diagnosis. 34 -* Integration of incomplete datasets using AI-driven probabilistic modeling. 35 -* Stratification of patients for personalized treatment. 36 - 37 37 == **The role of AI-powered annotation** == 38 38 39 39 To enhance standardization, interpretability, and clinical application, the framework integrates an AI-powered annotation system, which: 40 40 41 -* Assign sstructured metadata tags to diagnostic features.37 +* Assign structured metadata tags to diagnostic features. 42 42 * Provides real-time contextual explanations for AI-based classifications. 43 43 * Tracks longitudinal disease progression using timestamped AI annotations. 44 44 * Improves AI model transparency through interpretability tools (e.g., SHAP analysis). ... ... @@ -49,10 +49,6 @@ 49 49 1. Traditional Probabilistic Diagnosis 50 50 51 51 * AI provides multiple possible diagnoses, each assigned a probability percentage based on biomarker, imaging, and clinical data. 52 -* Example Output: 53 -** 75% Alzheimer's Disease 54 -** 20% Lewy Body Dementia 55 -** 5% Vascular Dementia 56 56 * Useful for differential diagnosis and treatment decision-making. 57 57 58 58 2. Tridimensional Diagnosis ... ... @@ -61,9 +61,9 @@ 61 61 (1) Etiology (genetic, autoimmune, metabolic, infectious) 62 62 (2) Molecular Biomarkers (amyloid-beta, tau, inflammatory markers, EEG patterns) 63 63 (3) Neuroanatomoclinical Correlations (brain atrophy, connectivity alterations) 64 -* This approach enables precise disease subtyping and biologically meaningful classification, particularly useful to track progression over time.56 +* This approach enables precise disease subtyping and biologically meaningful classification, particularly useful for tracking progression over time. 65 65 66 - For every patient case, both systems will be offered, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification.58 +Both systems will be offered for every patient case, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification. 67 67 68 68 69 69 == **The case of neurodegenerative diseases** == ... ... @@ -122,7 +122,7 @@ 122 122 123 123 == Who has access? == 124 124 125 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 117 +We welcome contributions from the global community. Join us as we transform CNS diagnostics and drive precision medicine forward through a collaborative, open-source approach. Let’s build the future of neurological diagnostics together! 126 126 ))) 127 127 128 128